Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Rituximab in Reducing Relapses in Children With Steroid-Sensitive Nephrotic Syndrome: An Open-label, Multi-center Clinical Study.

NCT07049172 is registered in ClinicalTrials.gov with Wuhan Children's Hospital as lead sponsor.

NCT NCT07049172
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07049172 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Rituximab in Reducing Relapses in Children With Steroid-Sensitive Nephrotic Syndrome: An Open-label, Multi-center Clinical Study.
Lead sponsor
Wuhan Children's Hospital
Phase
Not applicable
Overall status
Completed
Start date
January 1, 2021
Completion date
December 31, 2023
Enrollment
91 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

nephrotic syndrome in children